Afuco™ Anti-IL6R ADCC Therapeutic Antibody (Tocilizumab/Atlizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL6R. Tocilizumab (INN, or atlizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of RA in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-026 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL6R |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, FC, IP, FuncS, IF, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |